Abstract
Glycoprotein (GP) IIb\IIIa receptor plays a central role on platelets activation and its blockage has been a matter of interest since the beginning of percutaneous revascularization. After first promising trials, GP IIb\IIIa inhibitors (GPI) have been widely used in cath labs for about a decade, significantly improving prognosis for patients with STSegment Elevation Myocardial Infarction (STEMI). However, their utilization isn’t exempt from risks, mainly in form of bleeding disorders, which can negatively affect patients’ outcome. Moreover, routinary administration of thyenopiridines like clopidogrel and the introduction of new anticoagulants like bivalirudin significantly reduced indications for GPI. In this review, a risk/benefit evaluation GP IIb\IIIa inhibitors is presented and their indications for STEMI patients addressed to revascularization are discussed according to recent advances reported in literature.
Keywords: STEMI, glycoprotein IIb\IIIa, abcximab, eptifibatide, tirofiban, clopidogrel, bivalirudin, anticoagulants, bleeding disorders
Current Vascular Pharmacology
Title:GP IIb/IIIa Inhibitors for STEMI: Still the Gold Standard or an Old Survivor?
Volume: 10 Issue: 4
Author(s): Giuseppe Musumeci, Matteo Baroni and Roberta Rossini
Affiliation:
Keywords: STEMI, glycoprotein IIb\IIIa, abcximab, eptifibatide, tirofiban, clopidogrel, bivalirudin, anticoagulants, bleeding disorders
Abstract: Glycoprotein (GP) IIb\IIIa receptor plays a central role on platelets activation and its blockage has been a matter of interest since the beginning of percutaneous revascularization. After first promising trials, GP IIb\IIIa inhibitors (GPI) have been widely used in cath labs for about a decade, significantly improving prognosis for patients with STSegment Elevation Myocardial Infarction (STEMI). However, their utilization isn’t exempt from risks, mainly in form of bleeding disorders, which can negatively affect patients’ outcome. Moreover, routinary administration of thyenopiridines like clopidogrel and the introduction of new anticoagulants like bivalirudin significantly reduced indications for GPI. In this review, a risk/benefit evaluation GP IIb\IIIa inhibitors is presented and their indications for STEMI patients addressed to revascularization are discussed according to recent advances reported in literature.
Export Options
About this article
Cite this article as:
Musumeci Giuseppe, Baroni Matteo and Rossini Roberta, GP IIb/IIIa Inhibitors for STEMI: Still the Gold Standard or an Old Survivor?, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812737
DOI https://dx.doi.org/10.2174/157016112800812737 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Animal Models of Dementia and Alzheimer’s Disease for Pre-Clinical Testing and Clinical Translation
Current Alzheimer Research Role and Treatment of Mitochondrial DNA-Related Mitochondrial Dysfunction in Sporadic Neurodegenerative Diseases
Current Pharmaceutical Design Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Optimized Trace Analysis of Verapamil in Biological Fluids Using Solvent Bar Micro Extraction Technique Coupled with HPLC-UV Detection
Current Analytical Chemistry Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications
Cardiovascular & Hematological Disorders-Drug Targets COVID-19 in People with Diabetes: Perspectives from Saudi Arabia
Current Diabetes Reviews The Epidemiology of Sepsis
Current Pharmaceutical Design Effect of Using Nanoparticle-based Diesel Fuel on Enhancement of Performance and Emissions of Diesel Engines
Nanoscience & Nanotechnology-Asia Controlling the Flow of Energy: Inhibition and Stimulation of the Creatine Transporter
Current Enzyme Inhibition Recent Advances in the Use of Cyclodextrins in Antifungal Formulations
Current Topics in Medicinal Chemistry Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Current Drug Targets Problems in Stem Cell Therapy for Cardiac Repair and Tissue Engineering Approaches Based on Graphene and Its Derivatives
Current Stem Cell Research & Therapy Aliskiren in Patients with Diabetes: A Systematic Review
Current Vascular Pharmacology Cardiotoxicity of Tyrosine-Kinase-Targeting Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Dabigatran - A New Chapter in Anticoagulation
Cardiovascular & Hematological Agents in Medicinal Chemistry A Review on Preclinical Models of Ischemic Stroke: Insights Into the Pathomechanisms and New Treatment Strategies
Current Neuropharmacology Lung Ultrasound in the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Editorial (Thematic Issue: Current Research, Knowledge and Controversies on High Density Lipoprotein)
Current Medicinal Chemistry Repetitive Transient Phosphodiesterase-3 Inhibition Eliminates Non-ischemic Cardiac Remodeling and Failure
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)